Invention Grant
- Patent Title: Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
-
Application No.: US15421729Application Date: 2017-02-01
-
Publication No.: US09932313B2Publication Date: 2018-04-03
- Inventor: Gary D. Glick , Alexander R. Hurd , Clarke B. Taylor , Chad A. VanHuis
- Applicant: Lycera Corporation
- Applicant Address: US MI Ann Arbor
- Assignee: Lycera Corporation
- Current Assignee: Lycera Corporation
- Current Assignee Address: US MI Ann Arbor
- Agency: Goodwin Procter LLP
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61K31/44 ; A61K31/5377 ; C07D231/38 ; C07D231/40 ; C07D401/12 ; C07D405/12 ; C07D409/04 ; C07D409/12 ; C07D417/12 ; C07D487/14 ; C07D401/14 ; C07D413/12 ; C07D413/14 ; C07D403/12
Abstract:
The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Public/Granted literature
- US20170267643A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF Public/Granted day:2017-09-21
Information query
IPC分类:
